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Abstract Percutaneous coronary intervention has become
the most common and widely implemented method of heart
revascularization. However, the development of restenosis
remains the major limitation of this method. Photodynamic
therapy (PDT) recently emerged as a new and promising
method for the prevention of arterial restenosis. Here the
efﬁcacy of chlorin e6 in PDT was investigated in vitro using
human vascular smooth muscle cells (TG/HA-VSMCs) as
one of the cell types crucial in the development of reste-
nosis. PDT-induced cell death was studied on many levels,
including annexin V staining, measurement of the genera-
tion reactive oxygen species (ROS) and caspase-3 activity,
and assessment of changes in mitochondrial membrane
potential and fragmentation of DNA. Photosensitization of
TG/HA-VSMCs with a 170 lM of chlorin e6 and sub-
sequent illumination with the light of a 672-nm diode laser
(2 J/cm
2) resulted in the generation of ROS, a decrease in
cell membrane polarization, caspase-3 activation, as well as
DNA fragmentation. Interestingly, the latter two apoptotic
events could not be observed in photosensitized and illu-
minated NIH3T3 ﬁbroblasts, suggesting different outcomes
of the model of PDT in various types of cells. The results
obtained with human VSMCs show that chlorin e6 may be
useful in the PDT of aerial restenosis, but its efﬁcacy still
needs to be established in an animal model.
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Introduction
Ischemic heart disease caused by coronary artery athero-
sclerosis and its complications is the leading cause of
morbidity and mortality in developed countries. During the
last two decades, percutaneous coronary intervention (PCI)
has become the most common and widely implemented
method of heart revascularization (Hill et al. 2007).
Restenosis, which occurs in the initial 3–24 months after
revascularization in about 30–50% of cases, remains the
major limitation of the method (Moussavian et al. 2001).
Although the molecular basis of restenosis is not yet
fully understood, it is known that it is an inﬂammatory and
multifactoral process involving the activation and prolif-
eration of intimal smooth muscle cells and the migration of
adventitial cells (ﬁbroblasts) into the subintimal space,
which results in the production and deposition of extra-
cellular matrix elements and thus neointimal hyperplasia,
eventually leading to late lumen loss (Schiele 2005;
Toutouzas et al. 2004; Zubilewicz et al. 2001). Because
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vascular smooth muscle cells (VSMCs), control of their
proliferation or their elimination may be a good target in
the therapy of restenosis. It is worth mentioning that over
50 agents were shown to modulate intimal hyperplasia and
restenosis in animal models favorably, but few have been
shown to be effective in humans (Sobeh et al. 1995).
Photodynamic therapy (PDT) is an alternative and novel
approach to modulate the vascular response to injury
caused by PCI (Mansﬁeld et al. 2001; Moussavian et al.
2001) and has already been clinically approved for the
treatment of various proliferative diseases in oncology,
ophthalmology, and dermatology. PDT involves a photo-
sensitizing agent that accumulates selectively in the target
cells and its illumination with a low-power laser of
appropriate wavelength (preferably close to red) to gener-
ate cytotoxic reactive oxygen species (ROS). The effect of
PDT depends on the photosensitizing agent, its concen-
tration, as well as the cell type. PDT has been shown to
reduce proliferation and to induce cell-cycle arrest, apop-
tosis, autophagy, as well as necrosis-like cell death
(Buytaert et al. 2007; Granville et al. 2001a; Granville et al.
2001b; Heckenkamp et al. 1999; Kessel and Reiners 2007;
LaMuraglia et al. 2000). Several types of photosensitizer,
such as porphycene derivatives, 5-aminolevulinic acid,
photophrin II, chloroaluminium sulfonated phtalocyanine,
and Zn(II)-phtalocyanine, have been tested and proved to
be effective for photonangioplasty in animal models (Chen
et al. 2001; Derkacz et al. 2005; Eton et al. 1996; Kereiakes
et al. 2003; Magaraggia et al. 2006; Nagae et al. 2001).
Chlorin e6 (Fig. 1) is a member of the chlorin family with a
characteristic Soret band absorption at 400 nm and less
intense Q bands in the visible region of 450–700 nm
(Cunderlı ´kova ´ et al. 1999). Illumination of chlorin e6
results in the generation of an exited singlet-state molecule,
which results in the formation of highly reactive singlet
oxygen and the formation of ROS. The resulting oxidative
stress leads to impairment of mitochondria and endoplas-
mic reticulum function and, consequently, to execution of
the cell-death program (Buytaert et al. 2007; Gurinovich
et al. 1992; Kessel and Poretz 2000; Kessel et al. 1995).
From the few clinical experimental data on the inﬂuence
of PDT on vascular cells it is postulated that it induces
apoptotic processes in cells and thus results in loss of cell
viability (Granville et al. 2001a; Kessel et al. 2000). This
observation potentially favors PDT over other techniques,
as apoptosis does not induce much inﬂammatory response
within the vessel wall, which enables maintaining vascular
wall integrity. Chlorin e6 has good water and lipid solu-
bility properties and easily translocates through the cell
membrane. In cells, chlorin e6 has been shown to local-
ize to the membrane (Cunderlı ´kova ´ et al. 1999) and
mitochondria (Kessel and Poretz 2000). In a few experi-
ments with animal models, PDT with chlorin e6 was
demonstrated to inhibit arterial intimal hyperplasia after
both balloon injury and stent implantation (Heckenkamp
et al. 2004; Nagae et al. 2001; Wakamatsu et al. 2005), but
no data are available on the molecular effects of the action
of chlorin e6 on human vascular wall cells.
This paper presents a molecular in vitro study aimed at
assessing the time- and dose-dependent inﬂuence of PDT
with chlorin e6 on ﬁbroblasts and human smooth muscle
cells. We show a rapid generation of ROS after the illu-
mination of photosensitized cells and subsequent events,
including cellular membrane depolarization, mitochondrial
potential loss, caspase-3 activation, and DNA fragmenta-
tion. When PDT conditions optimal for vascular cells were
applied to PDT of NIH3T3 ﬁbroblasts, we observed the
induction of toxicity and phosphatidylserine presentation,
but not other apoptotic hallmarks such as DNA frag-
mentation or caspase-3 activation. The present paper
demonstrates that TG/HA-VSMCs undergo apoptosis as a
consequence of PDT, indicating the value of chlorin e6 for
animal studies but also showing possible drawbacks due to
differences in response of various cell populations to the
PDT.
Materials and Methods
Cell Cultures and Reagents
T/G HA-VSMCs, a human aortic smooth muscle cell line
established by telomerase transfection, were cultured in
F12 K medium supplemented with 2 mM L-glutamate
(Gibco, Invitrogen Corp., USA) and 0.1 mg/ml heparin
(Sigma-Aldrich, USA), 0.03 mg/ml endothelial cell growth
supplement (Sigma-Aldrich, USA), and 10% fetal calf
serum (FCS; Gibco, USA). NIH3T3 mouse embryonal
ﬁbroblasts were cultured in a 10-ml ﬂask in Dulbecco’s
Modiﬁed Eagle’s Medium (Ludwik Hirszfeld Institute of
Immunology and Experimental Therapy, Poland) supple-
mented with 10% FCS (Gibco, USA), 3% glutamate,
10 mM HEPES, 1 mM sodium pyruvate (all Sigma-
Aldrich, USA). The photosensitizer chlorin e6 (fotolon,
18-carboxy-20-(carboxymethyl)-8-ethenyl-13-ethyl-2,3,-
dihydro- 3,7,12,17-tetramethyl-21H, 23H-porphin-2-pro-
pionic acid; Haemato Polska) was prepared fresh in 0.9%
NaCl (POCh, Poland). Also used were 96- and 24-well
plates, 10 ml ﬂasks (Corning Costar, The Netherlands),
phosphate-buffered saline solution (PBS; Ludwik Hirszfeld
Institute of Immunology and Experimental Therapy,
Poland), Annexin V-FITC conjugate, and propidium iodide
(PI; Sigma-Aldrich, USA).
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In the dark and using coated tubes, plates, etc., 200,000
cells (in a 24-well plate) were pretreated with the indicated
concentration of chlorin e6 for 90 min in culture medium.
Then the plate was washed twice with warm PBS con-
taining 2.5% FCS and incubated for 30 min. The cells were
illuminated in a darkened room with 672-nm diode laser
light at a ﬂuence rate of 75 mW/cm
2 or 150 mW/cm
2 to
achieve total light doses of 0.6, 1.1, and 2 J/cm
2.
Microscopy
To prove the presence and assess the distribution of chlorin
e6 in cells, the cells (10,000/well, 250 ll) were cultured on
eight-chamber microscope slides (Nunc, USA). After 1 day
of culture the cells were treated with 17 lM of chlorin e6
for 10 min and washed twice with warm PBS. The pres-
ence of chlorin e6 inside the cell was assessed using a Carl
Zeiss ﬂuorescence microscope equipped with a UV lamp
and 43HS Filter Set (Carl Zeiss MicroImaging Inc.,
Germany).
MTS Assay
The toxicity of the PDT was assayed by the MTS assay
(Promega, USA) according to the supplier’s instructions.
Brieﬂy, 5,000 cells/well were cultured and subjected to the
PDT experiment. After 35 min of incubation, 20 llo f
MTS reagent was added. After 2 h, 490-nm absorbance
was read on a Vallac Victor2 plate reader.
Early Apoptosis Assessment by Annexin V Staining
Cells subjected to PDT were cultured for 45 min and then
detached using 1% trypsin (Gibco), washed twice with PBS
containing 2.5% FCS, and stained with 50 lg/ml Annexin
V-FITC conjugate in the presence 10 lg/ml PI for 10 min
at room temperature. The stained cells were analyzed using
a FACSCalibur ﬂow cytometer (Becton-Dickinson, USA)
and WinMDI 2.8 software.
Caspase-3 Activity
Caspase-3 activity in cell lysates was measured using a
Caspase-3 Cellular Activity Kit (Calbiochem, USA)
according to the manufacturer’s instructions. After illumi-
nation, the cells were incubated for 4 h and then lysed.
Caspase-3 Inhibitor I (Ac-DEVD-CHO) was used to test
the speciﬁcity of the caspase activation. The samples were
analyzed on a Vallac Victor2 plate reader. The readings
were converted to caspase-3 activity units (U) in 100 lgo f
protein according to a standard curve prepared using the
supplied human recombinant caspase-3.
Measurement of ROS
ROS concentration was assessed by measuring the 485-/
535-nm ﬂuorescence of H2DCFDA [6-carboxy-20,70-
dichlorodihydroﬂuorescein diacetate, di(acetoxymethyl
ester); Molecular Probes, USA]. Brieﬂy, 5,000 cells
(96-well plate) were incubated in the presence of 170 lM
chlorin e6 and 10 lMo fH 2DCFDA for 30 min in PBS
with 1% FCS. Then the cells were washed twice with warm
PBS with 2.5% FCS, cultured for 30 min in medium and
illuminated. Fluorescence readings were performed
directly after illumination. A blank-probe (cells and med-
ium) reading was used as the background and subtracted
from all the sample readings.
Measurement of Mitochondrial Membrane Potential
After washing with PBS, JC-1 (5,50,6,60-tetrachloro-
1,10,3,30-tetraethyl-benzimidazolylcarbocyanine iodide, 1 lM;
Molecular Probes, USA) was added to cells subjected
to PDT and the cells were incubated for 15 min at 37C.
Fig. 1 a Structure of chlorin
e6. The presence of the chlorin
ring gives the compound
ﬂuorescent and photochemical
properties. b Chlorin e6
distribution in the cell may be
directly observed using a
ﬂuorescence microscope
equipped with a UV lamp and
605–670 nm ﬁlter. Chlorin e6
rapidly translocates through
the cell membrane into the
cell and accumulates in the
cytoplasm. Representative
microphotography is shown
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mulation in the mitochondria. It indicates mitochondria
depolarization by a decrease in the red to green ﬂuores-
cence intensity ratio. The cell suspensions were analyzed
with a FACSCalibur ﬂow cytometer (Becton-Dickinson,
USA) according to the manufacturer’s instructions.
Detection of DNA Fragmentation
The detection of apoptosis was based on evaluating DNA
content with the use of PI and ﬂow cytometry. Brieﬂy, after
18 h of treatment, the cells were washed twice with PBS
containing 2.5% FCS, ﬁxed with 70% ethanol (POCh,
Poland) for 30 min at 4C, washed again with PBS, and
then stained with 10 ug/ml PI (50 without Ca
2?,M g
2?;
Sigma-Aldrich, USA) overnight at 4C. The cell suspen-
sions were analyzed with a FACSCalibur ﬂow cytometer
(Becton-Dickinson, USA). DNA content was evaluated on
the basis of FL-2 histograms using WinMDI 2.8 software.
Results
Chlorin e6 is Detectable Inside Cells As Early As
15 min After Treatment
The efﬁciency of the PDT model was studied using a
human aortic smooth muscle cell line (T/G HA-VSMC),
representing one of the cell types playing a crucial role in
the development of restenosis (Schiele 2005). Chlorin e6,
as a member the chlorin group, has strong photochemical
and ﬂuorescence properties (Cunderlı ´kova ´ et al. 1999)
(Fig. 1a). Thus, using a ﬂuorescence microscope we were
able to observe the cellular localization of chlorin e6. We
found that even 10 min of incubation of TG/HA-VSMCs
with 17 lM chlorin e6 is sufﬁcient for its cellular uptake
(Fig. 1b). The pattern of ﬂuorescence indicates a cyto-
plasmic localization of the compound, probably bound to
membrane structures. It is worth noting that a further
increase in incubation time had no effect on the observed
ﬂuorescence intensity or staining distribution (data not
shown).
PDT with Chlorin e6 Leads to the Generation
of ROS in Photosensitized Cells
We designed a model of PDT consisting of photosensitiz-
ing, washing, incubation, and illumination. The scheme of
the PDT experiment is shown in Fig. 2a. In an aqueous
environment, illumination of chlorin e6 leads to the gen-
eration of ROS, which is the basis of the PDT (Kessel and
Poretz 2000). We monitored ROS produced due to the
illumination of photosensitized TG/HA-VSMCs and found
a rapid threefold increase in ﬂuorescence due to the gen-
eration of free radicals immediately after the illumination
of the smooth muscle cells (Fig. 2b). In non-illuminated
cells we observed no increase in ROS concentration.
Phototoxicity of PDT with Chlorin e6
in Human TG/HA-VSMCs
Various combinations of chlorin e6 concentration, ranging
from 17 to 170 lM, and light doses of 0.6, 1.1, and 2 J/cm
2
were examined. The toxicity of PDT was determined by
measuring dehydrogenase enzyme activity using the col-
orimetric MTS assay. We found that chlorin e6 alone does
not induce signiﬁcant toxicity (Fig. 3a). Illumination alone
also did not induce toxicity measured by the MTS assay
(Fig. 3b). The TG/HA-VSMC model of PDT showed
almost linear relationships between light dose or chlorin e6
concentration and toxicity. Increasing the concentration of
chlorin e6 resulted in a gradual increase in toxicity when
the same light dose (2 J/cm
2) was used (Fig. 3a). Similarly,
in cells photosensitized with 170 lM chlorin e6, increasing
the light dose led to a gradual increase in toxicity (Fig. 3b).
The maximum effect of about 80% toxicity was observed
for 170 lM chlorin e6 and a light dose of 2 J/cm
2, and
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Fig. 2 a Scheme of the standard in vitro photodynamic therapy
experiment. Cells were plated 2 days prior to photosensitization, then
incubated for 1 h in the presence of chlorin e6, washed, incubated for
30 min, and illuminated in a dark room. b The generation of reactive
oxygen species (ROS) due to illumination of the photosensitized
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2
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These data suggest that there is no need to increase the drug
dose for the PDT above 170 lM, as it may result in dark
toxicity.
Cells Subjected to PDT Had Properties
of Apoptotic Cells
Both necrotic and apoptotic processes may be initiated by
the ROS generated by the illumination of photosensitized
cells. To discover the nature of the observed toxicity, we
studied a few aspects of apoptosis: phosphatidylserine
presentation, mitochondrial potential impairment, caspase-
3 activation, and DNA fragmentation (Fig. 4). Staining
with Annexin V and PI was performed to detect cells at an
early stage of apoptosis. We found that the illumination of
photosensitized cells leads to an increase in the population
of cells expressing phosphatidylserine (59% vs ca. 10% in
controls); at the same time there was also a slight increase
in both Annexin V-PI double-positive and PI-positive cells,
indicating a decrease in cell membrane integrity (Fig. 4a).
Further incubation (e.g. 4 h, data not shown) shifts the
Annexin V-positive population to Annexin V-PI double-
positive, showing a gradual loss of cell membrane integrity
during that time.
Programmed cell death is very often initiated by or
related to loss of function by the mitochondria, which is
reﬂected by a decrease in mitochondrial membrane
potential. It is known that ROS accumulation may be a
cause of disruption of mitochondrial function. This can be
studied using IC-1 dye, which changes color according to
the state of mitochondrial potential. We observed signiﬁ-
cant impairment of mitochondrial potential in about 50% of
the cells 3 h after PDT (Fig. 4b). In contrast to Annexin
V/PI staining, in which treatment with photosensitizer or
light alone did not lead to any changes in staining pattern,
we could observe here a slight but recurrent increase in the
population of cells with impaired mitochondrial potential
in the photosensitized but non-illuminated samples.
It is known that the disruption of mitochondria leads to
cytochrome c release to the cytoplasm, which activates a
cascade of caspases with the effector caspase-3 at the
bottom. We examined the activation of effector caspase-3
in the TG/HA-VSMCs subjected to PDT and found an
approximately threefold activation of caspase-3 in the
photosensitized and illuminated cells, but not in the illu-
minated control cells (Fig. 4C). Here we could also
observe a slight but recurrent increase in caspase activity in
photosensitized cells, indicating that chlorin e6 alone may
induce an apoptotic response.
The most known hallmark of apoptosis is DNA frag-
mentation. We found that our model of PDT leads to DNA
fragmentation in about 70% of cells 18 h after illumination
(Fig. 4d), indicating that chlorin e6-based PDT results in
classical apoptosis of VSMCs. Light or chlorin e6 alone
had no impact on DNA status.
Chlorin e6 PDT Results in Atypical Programmed Cell
Death in NIH3T3 Fibroblasts
We decided to test our previous observations on other cells.
We choose ﬁbroblasts as they may represent another cell
population present in restenotic plaque. We examined the
inﬂuence of chlorin e6 PDT (170 lM of chlorin e6 in
combination with a 2-J/cm
2 light dose) on NIH3T3 cells,
widely used as a ﬁbroblast model. We found that the PDT
also induces toxicity in NIH3T3 cells (Fig. 5a, b), but
NIH3T3 cells seem to be more sensitive to PDT than
TG/HA-VSMCs. Even 17 lM chlorin e6 in combination
with a 2-J/cm
2 light dose induced phototoxicity of 80% of
NIH3T3 cells (Fig. 5a). Also, the conditions which were
optimal for the PDT of TG/HA-VSMCs (170 lMo f
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2) had toxic effect on
80% of the NIH3T3 cells (Fig. 5b). These ﬁndings were
reﬂected by the results of Annexin V/PI staining, in which
increases in both Annexin V-positive and Annexin V-PI
double-positive cells were observed (Fig. 5c). It is worth
mentioning that the observed percentages of both Annexin
V-positive populations were larger than those for TG/HA-
VSMC. We did not observe phosphatidylserine presenta-
tion in any of the three control samples (data not shown).
However, illumination of photosensitized cells generated
much less (only a twofold increase) ROS than in TG/HA-
VSMCs. There was also a signiﬁcant increase in detectable
ROS in non-illuminated but photosensitized cells, sug-
gesting that, in contrast to TG/HA-VSMCs, the presence of
photosensitizer alone may have impact on the condition of
NIH3T3 cells (Fig. 5d). At the same time, regardless
of chlorin e6 concentration, we could also not detect
caspase-3 activation in the photosensitized and illuminated
NIH3T3 ﬁbroblasts (Fig. 5e); moreover, most of the
observed activity (dark bars) was not inhibited by the
caspase-3 inhibitor Ac-DEVD-CHO (gray bars), suggest-
ing impaired caspase-3 activation.
Discussion
Photodynamic therapy is a well-established and clinically
approved treatment of some types of cancer, premalignant
conditions, and macular degeneration (Biel 2007; Fien and
Oseroff 2007; Taub 2007; Woodburn et al. 1998). In car-
diology there are increasing attempts to design a PDT for
the treatment of restenosis (Pai et al. 2005; Rockson et al.
2000; Sobeh et al. 1995; Zubilewicz et al. 2001). To date,
the preferred option of the treatment of post-PCI restenosis
has been the use of drug-eluting stents (DESs) delivering
antiproliferative agents to the vessel wall. The introduction
of the ﬁrst generation of DESs, delivering rapamycin or
paclitaxel to the vessel wall, to clinical practice signiﬁ-
cantly reduced the incidence of restenosis. However,
complete inhibition of the healing response and delayed
endothelial regeneration of the thrombogenic surface of the
stent may increase the risk of late thrombosis ([1 year
after the index PCI) and vessel occlusion (Hill et al. 2007;
Schiele 2005; Toutouzas et al. 2004). The problem of life-
threatening in-stent thrombosis has raised concerns about
the safety of DESs (Weisz and Stone 2008), in light of
medium
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treatment of restenosis have become even more urgent.
As the vascular wall’s proliferative response to injury
was deﬁned against the background of restenosis, selective
antiproliferative treatment seems to hold promise to com-
bat this unsolved issue. Here we attempted to test the
suitability of chlorin e6 in the PDT of restenosis. Chlorin
e6 is a well-known and widely used photosensitizing agent;
however, its mode of action on human VSMCs has never
been tested. We designed an in vitro experimental model to
study the effect of chlorin e6 on human vascular cells, as
smooth muscle cells were shown to be the ﬁrst population
responding to vessel injury and to be crucial in the devel-
opment of restenosis (Landry et al. 1997). It was shown
that targeting this population of vascular cells is an effec-
tive strategy to prevent restenosis. The ﬁrst signs of dark
toxicity were noted at a concentration of 84 lM. We found
that despite the lack of any carrier, such as liposomes, and
despite the presence of serum [which may decrease the
bioavaibility of chlorin-based compounds (Bose and Dube
2006)], as little as 10 min of incubation was enough to
observe chlorin e6 inside the cells, which makes it suitable
for in vivo sensitizing. Studies performed by Dube et al.
(2006) on a similar compound, chlorin p6, showed its quick
clearance. It could be expected that chlorin e6, which has a
very similar structure, will have similar pharmacokinetics
properties, which would make it a good choice for PDT. As
was shown in previous studies, chlorin e6 may locate to
plasma membrane and/or mitochondria (Kessel and Poretz
2000). Our observed staining pattern rather suggests a
cytoplasmic location of chlorin e6 in human smooth
muscle cells.
The molecular mechanism of chlorin e6-based PDT
remains unclear, and most studies concentrate on tumor
cells. ROS or singlet oxygen generation and the induction
of endoplasmic reticulum stress and mitochondrial
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Fig. 5 NIH3T3 response to
chlorin e6 PDT. a Results of
MTS assay, illumination (laser,
2 J/cm
2) in the presence
(triangles) or absence (squares)
of the indicated concentration of
chlorin e6. b Toxicity induced
in the cell population after
illumination with the indicated
light dose in the presence
(triangles) or absence (squares)
of 170 lM chlorin e6;
c Phosphatidylserine
presentation and membrane
integrity test of NIH3T3 cells
subjected to PDT (170 lM
chlorin e6 and 2 J/cm
2).
Percentages of populations are
shown. A representative result
of one of three independent
experiments is shown.
d Reactive oxygen species
(ROS) as 485-/535-nm
ﬂuorescence of H2DCFDA
generated in photosensitized
and/or illuminated samples.
e Caspase-3 activity measured
in lysates photosensitized and/or
illuminated NIH3T3 cells
(dark bar). The light gray bar
represents caspase-3-like
activity observed in the
presence of the caspase-3
inhibitor Ac-DEVD-CHO
Arch. Immunol. Ther. Exp. (2010) 58:67–75 73dysfunction are the most common events. This may lead to
the execution of all kinds of cell-death programs, from
classical apoptosis to programmed necrosis or autophagy
(Buytaert et al. 2007). We studied many aspects of the
illumination-induced programmed cell death of VSMCs
and found a rapid induction of ROS, probably close to the
mitochondria. The earliest observed cell death-related
event, 45 min after illumination of the photosensitized
cells, was phosphatidylserine presentation on the surface of
the cellular membrane. The second, measured 3 h after
illumination, was the loss of mitochondrial potential.
Interestingly, both events correspond to the preferred
localization of chlorin e6 in cells. About 4 h after the
illumination of photosensitized cells, an approximately
threefold increase in caspase-3 activity was observed. As
the ﬁnal hallmark of apoptosis, DNA fragmentation was
observed after 18 h of incubation, showing that chlorin e6-
based PDT induces rapid classical apoptosis and indicating
its suitability for designing and testing animal models of
the treatment of restenosis.
It is known that restenosis is a complex disease also
involving other populations of cells, such as macrophages
(Farb et al. 2002) and ﬁbroblasts (Bayes-Genis et al. 2002;
Li et al. 2000). It is also not clear if targeting cells other
than VSMCs may be beneﬁcial in restenosis therapy. We
found that chlorin e6-based PDT applied under conditions
effective on VSMCs, despite a low generation of ROS, led
to a profound phototoxic effect on NIH3T3 ﬁbroblasts.
This may suggest that the phototoxicity of chlorin e6 is
mediated only by singlet oxygen. Phosphatidylserine pre-
sentation and the gradual increase in phototoxicity
observed in 24- an 48-h cultures indicates the occurrence of
cell death (not shown). In contrast to VSMCs, PDT of
NIH3T3 did not result in caspase-3 activation and DNA
fragmentation (not shown). This suggests that in the case of
chlorin e6-based PDT of the ﬁbroblasts, another cell-death
program is initiated, as was observed in HeLa cells under
oxidative stress (Chernyak et al. 2006). This is a good
illustration of the possibility of inducing a wide range of
cell-death programs, including autophagy (Kessel et al.
2000; Kessel and Reiners 2007), as a response to PDT, and
it should be noted that further evaluation of cell death in in
vitro and in vivo studies should not depend on one assay
(largely MTT or MTS), as that may lead to inaccurate
results. The nature of the observed differential response
may involve, for example, the pattern of expression of
Bcl-2 family proteins, especially Bax and Bcl-2, whose
role in PDT-induced apoptosis was shown by Granville
et al. (2001b), although the roles of other family members
should not be excluded.
Taken together, using an in vitro PDT model based on
human VSMCs we showed that the photosensitizer chlorin
e6 may be useful in designing PDT for treating restenosis.
In addition, we showed that PDT under conditions which
are optimal and effective on VSMCs induces non-apoptotic
cell death of NIH3T3 cells. The ﬁbroblasts appeared to be
more sensitive to PDT, indicating a source of potential
complications of chlorin e6-based PDT in vivo, which
targets multiple cell populations.
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